put, low-cost format because most allergen-specific IgE testing currently is performed in regional reference laboratories. To that end, the immunoRCA microarray assay has been adapted to glass slides with 16 microwells, each separated by a Teflon mask. Microarrays of 100 -400 spots can be printed in each microwell; consequently, it is possible to carry out ϳ4000 assays per slide. Each of these wells can be used to assay different patient samples or negative or positive controls. Internal control features are included on each array to permit more rigorous standardization of results for each patient or each allergen than is currently possible with CAP; this feature allows for more meaningful serial testing of allergic patients. Finally, semi-automation of the immunoRCA assays on allergen microarrays in this multiwell format has been implemented in our laboratory on an Beckman BioMek liquidhandling robot.
The microarray-based immunoRCA assay is applicable to other multiplexed antibody assays. For example, certain immunological reactions are caused by specific IgG 4 rather than IgE (10 ) . The use of an anti-human IgG 4 conjugated to a DNA primer complementary to a DNA circle that is different in sequence from the one coupled to the anti-human IgE antibody would allow the simultaneous measurement of allergen-specific IgG 4 and IgE. Such an assay would potentially be of use during allergen desensitization therapy or for monitoring response to anti-IgE therapy (11 ) . The enormous multiplexing capabilities of immunoRCA on microarrays, both spatial (i.e., the ability to detect multiple analytes on the array) and colorimetric (i.e., the ability to detect and differentiate multiple antibody types binding to each analyte), would potentially be useful for other clinical diagnostic tests involving detection of multiple specific antibodies, such as autoantibodies in suspected systemic autoimmune disorders, inflammatory arthritis, organ-specific autoimmune disorders, or in histocompatibility testing. Additional applications include infectious disease diagnostics with measurement of strain-and species-specific IgM and IgG, as well as in vitro testing of functional antibody responses in patients with suspected primary and secondary immunodeficiency diseases. Prolactin occasionally is present in serum in a macromolecular complex. The most common form is macroprolactin, an antibody-antigen complex of prolactin (PRL) and immunoglobulin G with a molecular mass of 150 -170 kDa (1) (2) (3) (4) . The PRL component remains reactive (to various degrees) in immunoassays for PRL (5) (6) (7) , and macroprolactin is cleared more slowly than PRL from the circulation, leading to apparent hyperprolactinemia (8 ) .
Macroprolactin and the Roche Elecsys Prolactin
Macroprolactin is bioactive in vitro but has minimal bioactivity in vivo, probably because of the failure of the high-molecular mass complex to cross the capillary mem- CAP  100  71  67  73  78  79  74  79  82  RCA  83  92  91  79  100  100  88  100  100 a CAP and RCA results were compared with SPTs performed as described in the text. Nine patients had a positive SPT to dust miles (21 negative), 10 patients had a positive SPT to cat dander (20 negative), and 14 patients had a positive SPT to peanuts (16 negative). A CAP score Ն1 was considered positive. An immunoRCA result was considered positive if fluorescence from microarray spots for a particular allergen was greater than the background signal from microarray spots of an anti-prostate-specific antigen antibody. An immunoRCA result was considered positive for mites if either D. farinae or D. pteronyssinus spots showed a positive signal.
brane to reach target PRL receptors (9 ) . Hyperprolactinemia attributable to macroprolactin may cause diagnostic confusion and lead to inappropriate treatment, and it is important that laboratories characterize the response of their assay to macroprolactin and identify macroprolactin when this is a cause of hyperprolactinemia (1, 5 ) . The Wallac Delfia immunofluorometric PRL assay reacts strongly with macroprolactin, and this response is well characterized (5, 6, 10, 11 ) . High concentrations of polyethylene glycol (PEG) precipitate macroprolactin from serum, and this principle has been used in a screening test for the presence of macroprolactin validated with the Delfia assay (5 ).
We studied the reaction of the PRL assay on the Roche Elecsys 2010 analyzer to macroprolactin and compared it with that of the Delfia assay. We also evaluated the PEG precipitation technique as a means of detecting macroprolactin as the cause of hyperprolactinemia in the Elecsys assay.
Precipitation PRL in the supernatant after precipitation of serum with PEG and in the diluted serum was measured as for untreated serum, using the Elecsys and AutoDelfia analyzers according to the manufacturers' instructions. Gelfiltration chromatography of serum PRL was carried out on a 1.5 ϫ 50 cm Sephacryl S-300 (Pharmacia) column as described previously (5 ) . Monomeric PRL and macroprolactin were quantified from the relative areas under the peaks and the total serum PRL results obtained by the Wallac AutoDelfia PRL assay.
In a retrospective study with stored samples, the Elecsys assay gave results similar to Delfia in samples containing only monomeric PRL, whereas in samples containing macroprolactin demonstrated by gel-filtration chromatography, the Elecsys assay gave higher results (Table 1) .
Mean recovery of PRL from standards (IS 84/500 in phosphate buffer; Wallac) after precipitation with PEG with the Elecsys assay was 106% (range, 103-110%). Mean recovery of PRL from serum (n ϭ 35) containing only monomeric PRL was 86% (range, 71-106%), indicating variable coprecipitation of PRL with serum proteins. The recovery of PRL after precipitation with PEG from serum containing macroprolactin was lower and showed a quantitative relationship proportional to the percentage of macroprolactin present, as determined by gel-filtration chromatography (Fig. 1A) . This relationship is emphasized by the line in Fig. 1A , which shows the recovery of PRL after precipitation with PEG in one sample, containing 93% immunoreactive PRL as macroprolactin, that had been diluted with various amounts of a sample containing only monomeric PRL. Repeated assays (n ϭ 12) over 3 months of PRL recovery after PEG precipitation, using a pool of frozen serum containing only monomeric PRL, gave a mean recovery of 85.1% and a CV of 4.1%.
PEG precipitation was applied prospectively to 139 consecutive serum samples with PRL Ͼ600 mIU/L identified over a period of 10 months in two laboratories using the Elecsys assay.
Recovery of PRL showed a bimodal frequency distribution (Fig. 1B) . A cutoff of 50% has been used and validated with the Delfia assay to identify the presence of macroprolactin (11 ) . Application of this cutoff to the data in Fig.  1 indicated that macroprolactin was the cause of hyperprolactinemia in 11 of the 69 samples from Southend (16%) and 12 of the 70 samples from Basildon (17%). All 11 samples with recoveries Ͻ50% from the Southend population were subjected to gel-filtration chromatography, which confirmed that macroprolactin was the predominant immunoreactive form of PRL in all of these samples.
Two samples were distributed to seven laboratories that use the Elecsys PRL assay and the PEG precipitation procedure: sample A, with a total PRL of 2982 mIU/L and containing macroprolactin that contributed 90% of the total PRL immunoreactivity (Delfia); and sample B, with a total PRL of 2004 mIU/L and containing only monomeric PRL. All laboratories found low recovery of PRL after PEG precipitation in sample A (6.5-9.0%) and normal recovery in sample B (81.3-92.0%).
We surmise that the Roche Elecsys PRL assay reacts strongly with macroprolactin and that macroprolactin is a common cause of hyperprolactinemia with this assay. Macroprolactin can be detected by low PRL recovery after precipitation with PEG, and the recovery allows an estimate of the monomeric PRL. We recommend that users of the Elecsys assay make their clinical colleagues aware that macroprolactin may cause apparent hyperprolactinemia and that samples from all patients with increased PRL be examined for the presence of macroprolactin by precipitation with PEG. It is interesting to note that the PRL assay on the Roche Enzymun system reacts less strongly with macroprolactin (7 ) but uses the same pair of antibodies as the Elecsys assay. However, the antibodies are coupled to different solid phases and use different signal-generation systems in the two assays.
We thank Roche Diagnostics (Lewes, UK) for providing the reagents for this work. Genetic polymorphisms in drug-metabolizing enzymes, transporters, receptors, and other drug targets have been linked to interindividual differences in the efficacy and toxicity of many medications (1, 2 ) . Knowledge of an individual's drug metabolism characteristics can help in avoiding adverse reactions or therapeutic failure and thus enhance therapeutic efficiency. One gene of particular interest in pharmacogenetics is the human multidrug resistance-1 (MDR1) gene. The MDR1 gene encodes an integral membrane protein, P-glycoprotein (PGP), whose function is the energy-dependent export of substances from the inside of cells to the outside (3 ). Many drugs are substrates of PGP. Therefore, expression and functionality of the MDR1 gene product can directly affect the therapeutic effectiveness of such compounds. This is of specific importance in cancer therapy, where high expression of MDR1 makes cancer cells refractory to treatment with many agents that are PGP substrates (4 ) .
MDR1 is also expressed on nonmalignant cells in various organs, e.g., the intestine and at the blood-brain (A), recovery of PRL after precipitation with PEG (Elecsys) and proportion of macroprolactin present (gel-filtration chromatography, Delfia assay). The line shows results for a serum containing 93% macroprolactin diluted with a serum containing only monomeric PRL. (B), frequency distribution of PRL recovery after precipitation of serum with PEG, using the Elecsys assay in two laboratories (Southend and Basildon).
